Can a patient with a decreased ejection fraction, atrial fibrillation (AFib), and low cardiac output syndrome after mitral valve repair via thoracotomy, who is newly started on metoprolol (beta blocker) and apixaban (factor Xa inhibitor), experience a normal post-operative course with worsening fatigue and shortness of breath (dyspnea) symptoms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Yes, this can be a normal post-operative course after mitral valve repair surgery, and the current symptoms are likely to improve as the heart adjusts to the repaired valve and the surgical inflammation subsides. Patients typically begin to feel significant improvement in heart function around 6-8 weeks after surgery, with full recovery taking 3-6 months. The current symptoms of fatigue, shortness of breath, atrial fibrillation, and temporarily reduced ejection fraction (50-55%) are common during early recovery. The body needs time to heal from the surgical trauma, adapt to the repaired valve, and resolve post-operative inflammation. The prescribed medications (metoprolol to control heart rate and apixaban for anticoagulation) are standard to manage post-operative atrial fibrillation and prevent clots, as recommended by the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation 1. During this recovery period, patients should follow a gradual return to activities, starting with short walks and slowly increasing activity as tolerated. It's essential to attend all follow-up appointments, take medications as prescribed, and report any worsening symptoms like increased shortness of breath, chest pain, or swelling. While the current symptoms may be concerning, they often resolve as the heart adjusts to the repaired valve and the surgical inflammation subsides. If symptoms persist beyond 8-12 weeks or worsen significantly, additional evaluation would be warranted, and treatment should be guided by the principles outlined in the 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults 1. Key aspects of management include monitoring fluid intake and output, vital signs, body weight, and clinical signs of systemic perfusion and congestion, as well as adjusting medications and diuretic regimens as needed to relieve congestion and maintain systemic perfusion.

From the Research

Post-Operative Course and Heart Function Improvement

  • The patient's current symptoms, such as fatigue and shortness of breath (SOB), could be part of the normal post-operative course after cardiac surgery, including mitral valve repair 2, 3.
  • The drop in ejection fraction to 50-55% may indicate some degree of cardiac dysfunction, which can be a concern after surgery 4.
  • Atrial fibrillation (a fib) is a common complication after cardiac surgery, and the use of beta-blockers like metoprolol can help control the ventricular rate 5, 6.
  • The patient's new medications, metoprolol and apixaban, are commonly used to manage conditions like a fib and prevent blood clots, but may not directly address the underlying issue of low cardiac output 5, 6.

Timeline for Improvement

  • The timeline for improvement in heart function after cardiac surgery can vary depending on individual factors, such as the type of surgery, overall health, and presence of comorbidities 2, 3.
  • Some patients may start to feel better within a few weeks after surgery, while others may take several months to recover 3.
  • It is essential to closely monitor the patient's condition and adjust their treatment plan as needed to ensure optimal recovery and management of any potential complications 2, 4.

Management of Heart Failure with Preserved Ejection Fraction (HFpEF)

  • The patient's symptoms and reduced ejection fraction may be indicative of HFpEF, which can be challenging to diagnose and manage 2, 3.
  • A comprehensive approach to management, including optimization of risk factors, treatment of comorbidities, and use of medications like sodium-glucose cotransporter 2 inhibitors, may be necessary to improve outcomes in patients with HFpEF 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Ejection Fraction Pros and Cons: JACC State-of-the-Art Review.

Journal of the American College of Cardiology, 2018

Research

Use of beta-blockers in atrial fibrillation.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.